These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3475267)

  • 1. The adverse effects of fluoroquinolones.
    Smith CR
    J Antimicrob Chemother; 1987 Jun; 19(6):709-11. PubMed ID: 3475267
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gyrase inhibitors: unwanted central nervous system effects].
    Rietbrock N; Staib AH
    Dtsch Med Wochenschr; 1987 Jan; 112(5):201. PubMed ID: 3467948
    [No Abstract]   [Full Text] [Related]  

  • 3. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC; Wolfson JS
    Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302
    [No Abstract]   [Full Text] [Related]  

  • 4. Quinolones.
    Shah PM
    Prog Drug Res; 1987; 31():243-56. PubMed ID: 3326031
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL; Jones RN
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Delmee M; Avesani V
    Antimicrob Agents Chemother; 1986 Feb; 29(2):374-5. PubMed ID: 2940968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluoroquinolones].
    Baykal M; Akalin E
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of new quinolones.
    Lode H; Höffken G; Prinzing C; Glatzel P; Wiley R; Olschewski P; Sievers B; Reimnitz D; Borner K; Koeppe P
    Drugs; 1987; 34 Suppl 1():21-5. PubMed ID: 3481323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Teengs JP; Baur C
    Eur J Respir Dis Suppl; 1986; 146():585-90. PubMed ID: 3465584
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical use of the quinolones.
    Neu HC
    Lancet; 1987 Dec; 2(8571):1319-22. PubMed ID: 2890913
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.